RRAS and breast cancer: Finally, overexpression of EPHB2 has been detected in human cholangiocarcinoma (CCA), cutaneous squamous cell carcinoma (cSCC) and cervical cancer where it regulates an EMT program through R-Ras activation [46–48] while EPHB2 cytosolic localization has been shown to predict poor survival in breast cancer patients [49].